Lack of tocilizumab effect on mortality in COVID19 patients.
Gregory E HoltMayank BatraMukunthan MurthiShweta KambaliKayo SantosMaria Virginia Perez BastidasHuda AsifSara HaddadiSixto AriasMehdi MirsaeidiPublished in: Scientific reports (2020)
Off-label tocilizumab use in COVID-19 patients reflects concern for cytokine release syndrome. Comparison of matched COVID-19 pneumonia patients found elevated IL-6 levels correlated with mortality that did not change with tocilizumab administration. Correlating mortality with increased IL-6 doesn't imply causality however lack of improvement by tocilizumab requires further clinical trial alterations.
Keyphrases
- rheumatoid arthritis
- sars cov
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- cardiovascular events
- clinical trial
- end stage renal disease
- coronavirus disease
- risk factors
- newly diagnosed
- peritoneal dialysis
- type diabetes
- cardiovascular disease
- emergency department
- randomized controlled trial
- case report
- intensive care unit
- systemic lupus erythematosus
- study protocol
- open label
- phase ii
- double blind
- clinical evaluation